Comparative evaluation of nephrotoxicity and management by macrophages of intravenous pharmaceutical iron formulations

PLoS ONE

Volumn 10, Issue 5, 2015, Pages

  Connor, James R ^a   Zhang, Xuesheng ^a   Nixon, Anne M ^a   Webb, Becky ^a   Perno, Joseph R ^b,c  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b Luitpold Pharmaceuticals Inc   (United States)

^c VILLANOVA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FERRIC CARBOXYMALTOSE; FERRIC GLUCONATE; FERRITIN; FERROPORTIN; FERROUS ION; FERUMOXYTOL; IRON; IRON DEXTRAN; IRON ISOMALTOSE; IRON SACCHARATE; LIPID; TUMOR NECROSIS FACTOR ALPHA; CATION TRANSPORT PROTEIN; DISACCHARIDE; FERRIC ION; FERRIC OXIDE, SACCHARATED; HEPCIDIN; IRON ISOMALTOSIDE 1000; MAGNETITE; MALTOSE; METAL TRANSPORTING PROTEIN 1; SACCHARIC ACID; TUMOR NECROSIS FACTOR;

ADULT; ANIMAL CELL; ARTICLE; CELL STRESS; CELL VIABILITY; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG FORMULATION; HUMAN; HUMAN CELL; IN VIVO STUDY; IRON DEFICIENCY; IRON TRANSPORT; KIDNEY CORTEX; KIDNEY HOMOGENATE; LIPID PEROXIDATION; MACROPHAGE; NEPHROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PERITONEUM MACROPHAGE; RAT; ANALOGS AND DERIVATIVES; ANIMAL; CELL LINE; CELL SURVIVAL; CYTOLOGY; DRUG EFFECTS; EPITHELIUM CELL; KIDNEY; METABOLISM; PRIMARY CELL CULTURE;

RATTUS;

ANIMALS; CATION TRANSPORT PROTEINS; CELL LINE; CELL SURVIVAL; DISACCHARIDES; EPITHELIAL CELLS; FERRIC COMPOUNDS; FERRITINS; FERROSOFERRIC OXIDE; GLUCARIC ACID; HEPCIDINS; HUMANS; IRON; IRON-DEXTRAN COMPLEX; KIDNEY; LIPID PEROXIDATION; MACROPHAGES, PERITONEAL; MALTOSE; OXIDATIVE STRESS; PRIMARY CELL CULTURE; RATS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84929377825     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0125272     Document Type: Article

References (38)

1. Vogel SC. Parenteral iron supplementation in patients with end stage renal disease. ANNA J. 1998 Dec; 25(6): 625-30. PMID: 10188399
2. Bayraktar UD, Bayraktar S. Treatment of iron deficiency anemia associated with gastrointestinal tract diseases. World J Gastroenterol. 2010 Jun 14; 16(22): 2720-5. PMID: 20533591
3. Kovesdy CP, Kalantar-Zadeh K. Iron therapy in chronic kidney disease: current controversies. J Ren Care. 2009 Dec; 35 Suppl 2:14-24. doi: 10.1111/j.1755-6686.2009.00125.x PMID: 19891681
4. Jomova K, Vondrakova D, Lawson M, Valko M. Metals, oxidative stress and neurodegenerative disorders. Mol Cell Biochem. 2010 Aug 22.
5. Groves JT. The bioinorganic chemistry of iron in oxygenases and supramolecular assemblies. Proc Natl Acad Sci U S A. 2003 Apr 1; 100(7):3569-74. PMID: 12655056
6. Shinobu LA, Beal MF. The role of oxidative processes and metal ions in aging and Alzheimer Disease. In: Connor J.R., Editor, Metals and oxidative damage in neurological disorders, 1997. Plenum Press, New York, pp. 237-276.
7. Cavdar C, Temiz A, Yeniçerioʇlu Y, Calişkan S, Celik A, Sifil A, et al. The effects of intravenous iron treatment on oxidant stress and erythrocyte deformability in hemodialysis patients. Scand J Urol Nephrol. 2003; 37(1):77-82. PMID: 12745750
8. Michelis R, Gery R, Sela S, Shurtz-Swirski R, Grinberg N, Snitkovski T, et al. Carbonyl stress induced by intravenous iron during haemodialysis. Nephrol Dial Transplant. 2003 May; 18(5):924-30. PMID: 12686666
9. Lyseng-Williamson KA, Keating GM. Ferric carboxymaltose: a review of its use in iron-deficiency anaemia. Drugs. 2009; 69(6):739-56. doi: 10.2165/00003495-200969060-00007 PMID: 19405553
10. Garrick MD, Garrick LM. Cellular iron transport. Biochim Biophys Acta. 2009 May; 1790(5):309-25. Epub 2009 Apr 1. doi: 10.1016/j.bbagen.2009.03.018 PMID: 19344751
11. Ganz T, Nemeth E. Regulation of iron acquisition and iron distribution in mammals. Biochim Biophys Acta. 2006 Jul; 1763(7):690-9. PMID: 16790283
12. Sullivan JL. Macrophage iron, hepcidin, and atherosclerotic plaque stability. Exp Biol Med (Maywood). 2007 Sep; 232(8):1014-20. PMID: 17720947
13. Walter PB, Harmatz P, Vichinsky E. Iron metabolism and iron chelation in sickle cell disease. Acta Haematol. 2009; 122(2-3):174-83. doi: 10.1159/000243792 PMID: 19907145
14. Corna G, Campana L, Pignatti E, Castiglioni A, Tagliafico E, Bosurgi L, et al. Polarization dictates iron handling by inflammatory and alternatively activated macrophages. Haematologica 2010; 95 (11):1814-1822; doi: 10.3324/haematol.2010.023879 PMID: 20511666
15. Rozen-Zvi B, Gafter-Gvili A, Paul M, Leibovici L, Shpilberg O, Gafter U. Intravenous versus oral iron supplementation for the treatment of anemia in CKD: systematic review and meta-analysis. Am J Kidney Dis. 2008 Nov; 52(5):897-906. doi: 10.1053/j.ajkd.2008.05.033 PMID: 18845368
16. Robinson AP, White TM, Mason DW. Macrophage heterogeneity in the rat as delineated by two monoclonal antibodies MRC OX-41 and MRC OX-42, the latter recognizing complement receptor type 3. Immunol. 1986 Feb; 57(2): 239-247.
17. Ito D, Imai Y, Ohsawa K, Nakajima K, Fukuuchi Y, Kohsaka S. Microglia-specific localisation of a novel calcium binding protein, Iba1. Mol Brain Res. 1998 June; 57(1):1-9. PMID: 9630473
18. Arosio P, Ingrassia R, Cavadini P. Ferritins: a family of molecules for iron storage, antioxidation and more. Am J Physiol Cell Physiol. 2007 Aug; 293(2):C641-9. PMID: 17459943
19. Cohen LA, Gutierrez L, Weiss A, Leichtmann-Bardoogo Y, Zhang DL, Crooks DR, et al. Serum ferritin is derived primarily from macrophages through a nonclassical secretory pathway. Blood. 2010 Sep 2; 116(9):1574-84. doi: 10.1182/blood-2009-11-253815 PMID: 20472835
20. Preza GC, Pinon R, Ganz T, Nemeth E. Cellular Catabolism of the Iron-Regulatory Peptide Hormone Hepcidin. 2013; PLoS ONE 8(3): e58934. doi: 10.1371/journal.pone.0058934 PMID: 23536837
21. Fisher J, Devraj K, Ingram J, Slagle-Webb B, Madhankumar AB, Liu X, et al. Ferritin: a novel mechanism for delivery of iron to the brain and other organs. Am J Physiol Cell Physiol. 2007 Aug; 293(2): C641-9. PMID: 17459943
22. Martinez FO, Helming L, Gordon S. Alternative activation of macrophages: an immunologic functional perspective. Annu Rev Immunol. 2009; 27:451-83. doi: 10.1146/annurev.immunol.021908.132532 PMID: 19105661
23. Bishu K, Agarwal R. Acute injury with intravenous iron and concerns regarding long-term safety. Clin J Am Soc Nephrol. 2006 Sep; 1 Suppl 1:S19-23. PMID: 17699372
24. Torti SV and Torti FM. Iron and cancer: more ore to be mined. Nature Reviews Cancer 13, 342-355 (May 2013) | doi: 10.1038/nrc3495 PMID: 23594855
25. Valko M, Morris H, Cronin MT. Metals, toxicity and oxidative stress. Curr Med Chem. 2005; 12 (10):1161-208. PMID: 15892631
26. Zager RA, Johnson AC, Hanson SY. Parenteral iron nephrotoxicity: potential mechanisms and consequences. Kidney Int. 2004 Jul; 66(1):144-56. PMID: 15200421
27. Zager RA, Johnson AC, Hanson SY, Wasse H. Parenteral iron formulations: a comparative toxicologic analysis and mechanisms of cell injury. Am J Kidney Dis. 2002 Jul; 40(1):90-103. PMID: 12087566
28. Johnson AC, Becker K, and Zager RA. Parenteral iron formulations differentially affect MCP-1, HO-1, and NGAL. Am J Physiol Renal Physiol 299: F426-F435, 2010. doi: 10.1152/ajprenal.00248.2010 PMID: 20504881
29. Tolouian R, Rajabi B, Boman D, Bilbao J, Gupta A. Iron infusion and deposition in the kidney. Clin Nephrol. 2013 Mar; 79(3):237-40. doi: 10.5414/CN107361 PMID: 23182397
30. Recalcati S, Locati M, Gammella E, Invernizzi P, Cairo G. Iron levels in polarized macrophages: regulation of immunity and autoimmunity. Autoimmun Rev. 2012 Oct; 11(12):883-9. doi: 10.1016/j.autrev.2012.03.003 PMID: 22449938
31. Zager RA, Johnson AC, Hanson SY, Lund S. Parenteral iron compounds sensitize mice to injury-initiated TNF-alpha mRNA production and TNF-alpha release. Am J Physiol Renal Physiol. 2005 Aug; 289 (2):F289-97. PMID: 15798091
32. Breborowicz A, Polubinska A, Breborowicz M, Simon M, Wanic-Kossowska M, Oreopoulos DG. Peritoneal effects of intravenous iron sucrose administration in rats.Transl Res. 2007 Jun; 149(6):304-9. PMID: 17543848
33. Kakhlon O, Cabantchik ZI. The labile iron pool: characterization, measurement, and participation in cellular processes. Free Radic Biol Med. 2002 Oct; 3(8):1037-46. PMID: 12374615
34. Imlay JA, Chin SM, Linn S. Toxic DNA Damage by Hydrogen Peroxide through the Fenton Reaction in vivo and in vitro. Science. 1988 April; 240(4852):640-2. PMID: 2834821
35. Weiss G. Iron metabolism in the anemia of chronic disease. Biochim Biophys Acta. 2009 Jul; 1790 (7):682-93. doi: 10.1016/j.bbagen.2008.08.006 PMID: 18786614
36. Ganz T, Nemeth E. Iron sequestration and anemia of inflammation. Semin Hematol. 2009 Oct; 46 (4):387-93. doi: 10.1053/j.seminhematol.2009.06.001 PMID: 19786207
37. Sturm B, Goldenberg H, Scheiber-Mojdehkar B.Transient increase of the labile iron pool in HepG2 cells by intravenous iron preparations. Eur J Biochem. 2003 Sep; 270(18):3731-8. PMID: 12950256
38. Ternes N, Scheiber-Mojdehkar B, Landgraf G, Goldenberg H, Sturm B. Iron availability and complex stability of iron hydroxyethyl starch and iron dextran a comparative in vitro study with liver cells and macrophages. Nephrol Dial Transplant. 2007 Oct; 22(10):2824-30. PMID: 17556418